首页> 外文OA文献 >Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects

【2h】

Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects

机译：血浆中PCSK9水平升高对非家族性高胆固醇血症和杂合子型家族性高胆固醇血症的患者均有害，而与低密度脂蛋白受体缺陷无关

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Lambert Gilles; Petrides Francine; Chatelais Mathias; Blom Dirk J.; Choque Benjamin; Tabet Fatiha; Wong Gida; Rye Kerry-Anne; Hooper Amanda J.; Burnett John R.; Barter Philip J.; Marais A. David;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects [J] . LambertG., PetridesF., ChatelaisM., Journal of the American College of Cardiology . 2014,第22期

机译：升高的血浆PCSK9水平对非血密高胆固醇血症和杂合族家族性高胆固醇血症的患者同样有害，无论低密度脂蛋白受体缺损如何
2. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects [J] . LambertG., PetridesF., ChatelaisM., Journal of the American College of Cardiology . 2014,第22期

机译：血浆PCSK9水平升高对非家族性高胆固醇血症和杂合性家族性高胆固醇血症的患者同样有害，而与低密度脂蛋白受体缺陷无关
3. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial [J] . RaalF., ScottR., SomaratneR., Circulation: An Official Journal of the American Heart Association . 2012,第20期

机译：AMG 145的低密度脂蛋白胆固醇降低作用，对杂合子家族性高胆固醇血症患者的前蛋白转化酶枯草杆菌蛋白酶/ kexin 9型丝氨酸蛋白酶的单克隆抗体：PCSK9抑制可降低LDL-C对杂合子家族性高胆固醇血症（RUTHERFORD）的影响试用
4. Plasma levels of SCD40L are associated with HDL-cholesterol and apoA-1 in patients with clinical diagnosis of familial hypercholesterolemia (FH). [C] . Idzior-Walus B., Hubalewska-Dydejczyk A., Walus-Miarka M., International Congress on Coronary Artery Disease . 2009

机译：SCD40L的血浆水平与家族性高胆固醇血症（FH）临床诊断患者的HDL-胆固醇和APOA-1相关。
5. Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy [O] . Frederick Raal, Vanessa Panz, Andrew Immelman, 2013

机译：未治疗的杂合子或纯合子家族性高胆固醇血症患者的PCSK9水平升高以及对大剂量他汀类药物治疗的反应
6. 0447: Elevated plasma PCSK9 is equally detrimental for non-familial hypercholesterolemic (non-FH) and heterozygous FH patients, irrespective of their LDL receptor defects [O] . Lambert Gilles 2014

机译：0447：血浆PCSK9升高对非家族性高胆固醇血症（non-FH）和杂合性FH患者同样有害，无论其LDL受体缺陷如何

Elevated Plasma PCSK9 Level Is Equally Detrimental for Patients With Nonfamilial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia, Irrespective of Low-Density Lipoprotein Receptor Defects

著录项

引文网络

相似文献

相关主题

期刊订阅